Labcorp is at the forefront of diagnostics research for Alzheimer's disease.

Labcorp is working hard to help over 6 million people in the US living with AD and over 80 million adults between 50-70 years whose second biggest health fear is AD. By combining the power of high precision technology with artificial intelligence, we are actively studying blood-based biomarkers, like pTau and NfL, and working with pharmaceutical partners to provide clear, objective answers to clinicians, patients, and families.

APOE Alzheimer’s Risk testing by Labcorp

This test detects the presence of the Apolipoprotein E (APOE)-4 variant, which is associated with an increased risk of late-onset (age >60-65) Alzheimer's disease (AD). The APOE4 variant increases the risk for late-onset Alzheimer's disease and may contribute to the pathology of the disease through influence on β-amyloid, inflammation, or other processes.